SMNROTCPharmaceutical PreparationsFiscal year ends December 31Also trades as SMNRW

Semnur Pharmaceuticals, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$0.43+0.03 (+6.75%)

Close on Oct 19, 2026

Market cap: $98.30M
P/E (TTM): –
Dividend yield: –

Semnur Pharmaceuticals, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2022-01-04
Cash & Equivalents	0.02	0.01	0.01	0.82	0
Cash & Short-Term Investments	0.02	0.01	0.01	0.82	0
Prepaid Expenses & Other	0.58	0.00	0.00	0.09	–
Other Current Assets	0	5.98	–	–	–
Total Current Assets	0.60	6.00	0.21	0.91	–
Property, Plant & Equipment	0.75	0.69	–	–	–
Gross Property, Plant & Equipment	0.78	0.71	–	–	–
Accumulated Depreciation	-0.03	-0.03	–	–	–
Total Assets	1.35	6.68	51	86	–
Accounts Payable	5.91	0	–	1.29	–
Accrued Expenses	0.74	0.04	–	–	–
Total Current Liabilities	10	0.04	5.60	1.29	–
Total Liabilities	22	49	8.49	4.18	–
Preferred Stock	0.00	0	–	0	–
Common Stock	0.02	0.02	–	0.00	–
Additional Paid-In Capital	255	73	–	0	–
Retained Earnings	-276	-115	-8.28	-3.27	–
Shareholders' Equity	-21	-43	-38	-3.27	0
Total Equity	-21	-43	-38	-3.27	0
Total Liabilities & Equity	1.35	6.68	51	86	–
Shares Outstanding(shares)	230	200	–	–	–
Deposits	–	0.08	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 505.0%

Financial strength

Current ratio: 0.11
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 0.4%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –